Cargando…

AHNAK2 is a potential prognostic biomarker in patients with PDAC

BACKGROUND: AHNAK nucleoprotein 2 (AHNAK2) belongs to the AHNAK protein family. The studies of AHNAK2 are limited. A recent study reported that AHNAK2 might be a biomarker for pancreatic ductal adenocarcinoma (PDAC); however, tissue-based experiments have not been conducted. The aim of this study wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Di, Wang, Junxiong, Shi, Xiaoyan, Yue, Bing, Hao, Jianyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458247/ https://www.ncbi.nlm.nih.gov/pubmed/28423668 http://dx.doi.org/10.18632/oncotarget.15990

Ejemplares similares

AHNAK2 is a biomarker and a potential therapeutic target of adenocarcinomas: AHNAK2 is a biomarker for adenocarcinomas
por: Xu, Meng, et al.
Publicado: (2022)

The Obscure Potential of AHNAK2
por: Zardab, Mohamed, et al.
Publicado: (2022)

Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy
por: Koguchi, Dai, et al.
Publicado: (2021)

Bioinformatics analysis of the clinical value and potential mechanisms of AHNAK2 in papillary thyroid carcinoma
por: Xie, Zhenyu, et al.
Publicado: (2020)

AHNAK2 is a Novel Prognostic Marker and Oncogenic Protein for Clear Cell Renal Cell Carcinoma
por: Wang, Minglei, et al.
Publicado: (2017)

SDC1 and ITGA2 as novel prognostic biomarkers for PDAC related to IPMN
por: Zhang, Chuan-long, et al.
Publicado: (2023)

Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
por: Shao, Huilin, et al.
Publicado: (2021)

AHNAK2 Urinary Protein Expression as Potential Biomarker for Bladder Cancer Detection: A Pilot Study
por: Komina, Selim, et al.
Publicado: (2022)

AHNAK as a Prognosis Factor Suppresses the Tumor Progression in Glioma
por: Zhao, Zijin, et al.
Publicado: (2017)

AHNAKs roles in physiology and malignant tumors
por: Zhang, Shusen, et al.
Publicado: (2023)

Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment
por: Speth, Cornelia, et al.
Publicado: (2022)

The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
por: Wheatley, Roseanna C., et al.
Publicado: (2022)

AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma
por: Zhang, Shusen, et al.
Publicado: (2020)

AHNAK suppresses ovarian cancer progression through the Wnt/β-catenin signaling pathway
por: Cai, Yanlin, et al.
Publicado: (2021)

Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC
por: Strell, Carina, et al.
Publicado: (2017)

Diagnostic and prognostic value of STAP1 and AHNAK methylation in peripheral blood immune cells for HBV-related hepatopathy
por: Sun, Libo, et al.
Publicado: (2023)

Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection
por: Dai, Manxiong, et al.
Publicado: (2022)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

AHNAK and Inflammatory Markers Predict Poor Survival in Laryngeal Carcinoma
por: Dumitru, Claudia A., et al.
Publicado: (2013)

A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC)
por: Sun, Yuqi, et al.
Publicado: (2021)

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Cui, Yanan, et al.
Publicado: (2022)

AHNAK enables mammary carcinoma cells to produce extracellular vesicles that increase neighboring fibroblast cell motility
por: Silva, Thaiomara A., et al.
Publicado: (2016)

Transverse Space Charge Effect During Bunch Compression in PDAC1 and PDAC2 Compressor Ring
por: Franchetti, Giuliano
Publicado: (2000)

A novel methylation signature predicts inferior outcome of patients with PDAC
por: Gu, Minqi, et al.
Publicado: (2021)

Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC
por: Gundlach, Jan-Paul, et al.
Publicado: (2018)

Protein kinase B phosphorylates AHNAK and regulates its subcellular localization
por: Sussman, Joshua, et al.
Publicado: (2001)

AHNAK Contributes to Hepatocellular Carcinoma Growth by Interacting with IGF-1R
por: Li, Kang, et al.
Publicado: (2022)

Circulating miRNAs as Noninvasive Biomarkers for PDAC Diagnosis and Prognosis in Mexico
por: Álvarez-Hilario, Lissuly Guadalupe, et al.
Publicado: (2023)

WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4
por: Yin, Wenke, et al.
Publicado: (2023)

Scaling the immune incline in PDAC
por: Rojas, Luis A., et al.
Publicado: (2021)

Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma
por: Peng, Rui, et al.
Publicado: (2019)

Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition
por: Zhang, Zhiwen, et al.
Publicado: (2019)

The combination of PKM2 overexpression and M2 macrophages infiltration confers a poor prognosis for PDAC patients
por: Hu, Hai, et al.
Publicado: (2020)

Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC
por: Alhothali, Marwa, et al.
Publicado: (2019)

The human gene AHNAK encodes a large phosphoprotein located primarily in the nucleus
Publicado: (1993)

Ahnak1 abnormally localizes in muscular dystrophies and contributes to muscle vesicle release
por: Zacharias, Ute, et al.
Publicado: (2011)

AHNAK interaction with the annexin 2/S100A10 complex regulates cell membrane cytoarchitecture
por: Benaud, Christelle, et al.
Publicado: (2004)

Exome sequencing in a child with neurodevelopmental disorder and epilepsy: Variant analysis of the AHNAK2 gene
por: Vinci, Mirella, et al.
Publicado: (2022)

Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1
por: Li, Xin, et al.
Publicado: (2023)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1bku23rntg8ibph01fpfjb2f1q